by Wim Mees | Oct 13, 2022 | Team events
At myNEO we know a company is only as strong as its team! Therefore, we recently built on that team relationship. In August we both had a team-BBQ together with our families and breakfast in the office with the board members.by Wim Mees | Aug 17, 2022 | Team events
Work hard, play hard!At myNEO we have afterwork drinks every month, this time we decided to enjoy the nice weather and have our well-deserved drinks at summer bar, Gazon. Some sun, refreshing drinks, and great colleagues made sure this was a fun and...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).